The Profound Impacts of Precision Medicine, Genomic Sequencing on Cancer Care
Precision Oncology is helping NCI treat cancer based on specific genetic changes in a patient’s tumor by allowing them to target mutations that will lower toxicity and improve overall effectiveness of the treatment.
A clinical trial at the National Cancer Institute called NCI-MATCH showed how cancer patients could benefit from genomic sequencing and is now informing future trials on precision medicine.
The NCI Molecular Analysis for Therapy Choice Trial initially screened 6,000 patients and treated 1,300 of them by pairing certain medications with their specific tumors regardless of the cancer type. Future trials like ComboMATCH will now look at precision medicine to study how tumors respond to targeted treatments.
NCI Researchers Dr. Lindsay Harris and Dr. Peter O’Dwyer shared how precision oncology is expanding treatment options and increasing patients’ survival rates. They also discuss the importance of clinical trials like these for progressing the fight against cancer.
-
Dr. Lyndsay Harris Associate Director, Cancer Diagnosis Program NCI -
Dr. Peter O'Dwyer Group Co-Chair ECOG-ACRIN Cancer Research Group
-
Navy Pushes AI from Experiments to Everyday Warfighting Functions
The Navy’s hybrid fleet hinges on a common naval lexicon and trustworthy AI woven into every intelligence function.
6m watch -
Why Federal Experience Matters After Leaving Government
Jose Arrieta, former HHS CIO, discusses how federal civil servants can carry their high-stakes experience and resilience into careers beyond public service.
7m watch -
How the Marine Corps Is Building a High-Tech Future Fleet
The Marine Corps is leveraging AI to automate tedious tasks, enhance data readiness and accelerate mission-critical functions.
8m watch -
New NPS Challenge Aims to Rewrite How the Military Builds Missiles
Officials say focusing on design methods, not hardware, could unlock fast, low‑cost manufacturing for future munitions.
11m watch
